



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

**Sunday, June 30**

**The Skirvin Hilton Hotel, 1 Park Avenue**

7:30 AM – 8:30 AM      *Registration & Breakfast*  
Grand Ballroom Foyer, 2<sup>nd</sup> Floor

8:00 AM – 8:30 AM      *Welcome Address*  
James J Tomasek, PhD, Vice President for Research, University of Oklahoma Health Sciences Center (OUHSC)  
Robert S Mannel, MD, Director, Stephenson Cancer Center, OUHSC  
Danny N Dhanasekaran, Director MTCRO-COBRE, Stephenson Cancer Center, OUHSC

**COBRE Distinguished Speaker Plenary Lecture**

8:30 AM – 9:05 AM      *Lessons Learned from the Ovarian Cancer Moon Shot Program*  
Anil K Sood, MD, University of Texas MD Anderson Cancer Center

**Session I – Ovarian Cancer: New Perspectives**

Session Chairs: Yong Sang Song, MD, PhD  
Benjamin Tsang, PhD

9:05 AM – 9:25 AM      *The inflammatory cytokine IL-6 promotes EMT in ovarian cancer cells via down-regulating glucose-dependent autophagy*  
Ciro Isidoro, DSc, PhD, Università del Piemonte Orientale

9:25 AM – 9:45 AM      *Regulation of ovarian cancer metastatic colonization by paracrine signals from the metastatic niche*  
Anirban K Mitra, PhD, Indiana University School of Medicine-Bloomington

9:45 AM – 10:05 AM      *Molecular characteristics of rare epithelial ovarian tumors and therapeutic implication*  
Kwong K Wong, PhD, University of Texas MD Anderson Cancer Center

10:05 AM – 10:25 AM      *Role of AMPK in Ovarian Cancer: A Metabolic and Immune Perspective*  
Ramandeep Rattan, PhD, Henry Ford Hospital, Wayne State University

10:25 AM – 10:40 AM      **Break**

**Keynote Address**

10:40 AM – 11:15 AM      *Moving from Reactive to Proactive Medicine Through Data Science: Focus on Ovarian Cancer*  
William S Dalton, MD, PhD, M2Gen, Moffitt Cancer Center



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

**Session II – Precision Cancer Medicine: Data and Target Analysis**

Session Chairs: Ciro Isidoro, DSc, MD

Barbara Vanderhyden, PhD

11:15 AM – 11:35 AM *Integrative analysis of clinical and multi-omics data for precision cancer medicine*

Yong Sang Song, MD, PhD, Seoul National University Hospital

11:35 AM – 11:55 AM *Diagnostic model based on EV metagenome data for ovarian cancer*

Taesung Park, PhD, Seoul National University

11:55 AM – 12:15 PM *MicroRNA Therapeutics in cancer*

Johji Inazawa, MD, PhD, Medical Research Institute, Tokyo Medical and Dental University

12:15 AM – 12:35 PM *Targeting lncRNAs in Ovarian Cancer*

Danny N Dhanasekaran, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

12:35 PM – 1:30 PM **Lunch**

**Keynote Address**

1:30 PM – 2:05 PM *Epigenetic Approaches to Epithelial Ovarian Cancer*

Rugang Zhang, PhD, The Wistar Institute

**Session III – Ovarian Cancer: Target Discovery**

Session Chairs: Katherine Moxley, MD

Raghubir Athwal, PhD

2:05 PM – 2:25 PM *Monocytes and interferons as a therapeutic strategy for ovarian cancer*

Christina M Annunziata, MD, PhD, National Cancer Institute, National Institutes of Health

2:25 PM – 2:45 PM *Plasma Gelsolin: A Determinant of Chemosensitivity and A Prognostic Indicator of Stage 1 Disease and Residual Disease in Ovarian Cancer*

Benjamin K Tsang, PhD, University of Ottawa, Ottawa Hospital Research Institute

2:45 PM – 3:05 PM *Targetable Genetic Aberrations in Women's Cancer*

Pradeep Chaluvally-Raghavan, PhD, Medical College of Wisconsin

3:05 PM – 3:25 PM *Targeting Ovarian Cancer: Identifying a Novel Toll Way*

Shrikant Anant, PhD, University of Kansas Medical Center

3:25 PM – 3:45 PM *Metformin abrogates age-associated ovarian fibrosis in women*

Barbara C Vanderhyden, PhD, University of Ottawa, Ottawa Hospital Research Institute



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

3:45 PM – 4:00 PM      **Break**

**Session IV – Breast Cancer: Targeting Strategies**

Session Chairs: Takemi Tanaka, PhD  
Xin Zhang, PhD

- 4:00 PM – 4:20 PM      *Engineering of On-Chip Organotypic Tumor Microenvironment Models to Study Cancer Progression*  
Mehdi Nikkah, PhD, Arizona State University
- 4:20 PM – 4:40 PM      *NOS2 and COX2 as major drivers of poor outcome in ER- breast cancer. New therapeutic opportunities in a difficult disease*  
David A Wink, PhD, National Cancer Institute, National Institutes of Health
- 4:40 PM – 5:00 PM      *Nitric oxide synthase inhibition and immunogenic cell death through RNA editing*  
Jenny C Chang, MD, Houston Methodist Hospital
- 5:00 PM – 5:20 PM      *Role of DNPH1 in breast cancer*  
Ralf Janknecht, PhD, University of Oklahoma Health Sciences Center
- 5:20 PM – 5:40 PM      *IL-6 induces epigenetic changes to promote incomplete angiogenesis in human breast tumors*  
Kapaettu Satyamoorthy, PhD, Manipal Academy of Higher Education



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

**Monday, July 1**

**The Skirvin Hilton Hotel, 1 Park Avenue**

7:30 AM – 8:30 AM      *Registration & Breakfast*  
Grand Ballroom Foyer, 2<sup>nd</sup> Floor

**Keynote Address**

8:00 AM – 8:35 AM      *Implication of SIRT1 overexpression in growth and progression of human colon cancer cells and its inhibition by curcumin through covalent modification*  
Young-Joon Surh, PhD, Seoul National University

**Session V – Oncogenic Mechanisms: Newer Insights**

Session Chairs: Lawrence Rothblum, PhD  
John DiGiovanni, PhD

8:35 AM – 8:50 AM      *Understanding the role of XRN2 in radiation resistance*  
Julio C Morales, PhD, University of Oklahoma Health Sciences Center

8:50 AM – 9:10 AM      *Cohesion Fatigue as a Source of Chromosome Instability in Cancer*  
Gary J Gorbsky, PhD, Oklahoma Medical Research Foundation

9:10 AM – 9:30 AM      *Roles and Mechanisms of Tetraspanins CD82 and CD151 in the Invasion and Metastasis of Solid Malignant Tumors*  
Xin A Zhang, MD, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

9:30 AM – 9:50 AM      *EphA2 Suppresses Hepatocarcinogenesis via Mitotic Arrest and Inhibition of ERK and Akt Activities*  
Bingcheng Wang, PhD, Case Western Reserve University School of Medicine

9:50 AM – 10:10 AM      *NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival*  
Richard L Eckert, PhD, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine

10:10 AM – 10:25 AM      **Break**



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

**Session VI – Tumor Microenvironment: The Target Landscape**

Session Chairs: Jie Wu, PhD

Priyabrata Mukherjee, PhD


- 10:25 AM – 10:45 AM *Adipose Stromal Cells, CXCL12, and Prostate Cancer Progression*  
John DiGiovanni, PhD, University of Texas at Austin
- 10:45 AM – 11:05 AM *Investigating the complex roles of integrin alpha3-beta1 in carcinogenesis and modulation of the tumor microenvironment*  
C Michael DiPersio, PhD, Albany Medical College
- 11:05 AM – 11:25 AM *Targeting CAF secretory autophagy for cancer therapy*  
Sufi M Thomas, PhD, University of Kansas Medical Center
- 11:25 AM – 11:45 AM *The initiation of exosomal miRNA signaling in cancer cells*  
Wei-Qun Ding, PhD, University of Oklahoma Health Sciences Center
- 11:45 AM – 12:05 PM *Roles of sex steroids and their receptors in inflammation and cancer metastasis*  
Viroj Boonyaratanakornkit, PhD, Chulalongkorn University
- 12:05 PM – 12:20 PM *Analysis of migration associated treatment resistance in glioblastoma to identify novel therapeutics*  
James D Battiste, MD, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 12:20 PM – 1:00 PM **Lunch**

**Session VII – Natural Compounds: Therapeutic Targeting**

Session Chairs: Young Joon Surh, PhD

Chinthalapally V Rao, PhD

- 1:00 PM – 1:20 PM *Targeting Tumor Microenvironment: A holistic Approach for Prostate Cancer Chemoprevention by a Small Molecule Silibinin*  
Rajesh Agarwal, PhD, University of Colorado Denver School of Pharmacy
- 1:20 PM – 1:40 PM *PARP-1 inhibitor INO-1001 (3-aminobenzamide) inhibits non-canonical parthanatos-like cell death in human leukaemia*  
Marc F Diederich, PhD, Luxembourg & Seoul National University
- 1:40 PM – 2:00 PM *Intervention of Natural Bioactives on Ovarian Cancer*  
Chin-Kun Wang, MD, PhD, Chung Shan Medical University
- 2:00 PM - 2:20 PM *Sulforaphane is a novel inhibitor of lipogenesis in prostate cancer*  
Shivendra V Singh, PhD, UPMC Hillman Cancer Center, University of Pittsburgh
- 2:20 PM - 2:40 PM *Chinese herbal formula inhibits breast cancer cells in vitro by inducing apoptosis and attenuating inflammation*  
Tewin Tencomnao, PhD, Chulalongkorn University



**International Ovarian Cancer Research Consortium  
and  
International Symposium on Tumor Microenvironment**

2:40 PM – 2:55 PM      **Break**

**Session VIII – Pancreatic Cancer: Biology and Therapy**

Session Chairs: Min Li, PhD  
Richard Eckert, PhD

- 2:55 PM – 3:15 PM      *Wild-type KRAS exerts tumor suppression via cytoplasmic retention of YAP1*  
Gloria H Su, PhD, Columbia University Irving Medical Center
- 3:15 PM – 3:35 PM      *Develop a novel therapy for pancreatic cancer*  
Min Li, PhD, University of Oklahoma Health Sciences Center
- 3:35 PM – 3:55 PM      *The role of DCLK1 in immunosuppressive pancreatic cancer TME*  
Dongfeng Qu, PhD, University of Oklahoma Health Sciences Center
- 3:55 PM - 4:15 PM      *Targeting Mucins for Pancreatic Cancer Prevention/Treatment*  
Chinthalapally V Rao, PhD, University of Oklahoma Health Sciences Center

**Session IX – Cancer Discovery: Targets and Therapy**

Session Chairs: Shivendra Singh, PhD  
Rajesh Agarwal, PhD

- 4:15 PM – 4:35 PM      *High Throughput Proteomics Approach to Human Disease*  
Junmin Peng, PhD, St Jude Children's Research Hospital
- 4:35 PM – 4:55 PM      *Identifying therapeutic targets in Cancer*  
Priyabrata K Mukherjee, PhD, University of Oklahoma Health Sciences Center
- 4:55 PM – 5:15 PM      *Targeted therapy and resistance mechanisms in RET oncogene-associated cancer*  
Jie Wu, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 5:15 PM – 5:30 PM      *Optimization of an Antibody Therapy Against ELTD1 in a GBM Xenograft Model*  
Rheal A Towner, PhD, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation
- 5:30 PM – 5:45 PM      *miRNA signatures and response to platinum based chemotherapy in endometrial carcinoma, the search for predictive biomarkers of tumor response*  
Katherine M Moxley, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 5:45 PM – 6:00 PM      **Closing Remarks**  
Johji Inazawa, MD, PhD  
Yong Sang Song, MD, PhD  
Young-Joon Surh, PhD  
Ciro Isidoro, DSc, MD